Moderna's COVID-19 Vaccine Produced Neutralizing Titers Against All Variants Tested

  • Moderna Inc MRNA has announced new results from in vitro neutralization studies of sera from individuals vaccinated with its COVID-19 vaccine.
  • The COVID-19 shot produced neutralizing titers against all variants tested, including other versions of the Beta variant, three lineage variants of B.1.617, including Delta variants, the Eta variant (first identified in Nigeria); and the A.23.1 and A.VOI.V2 variants first identified in Uganda and Angola, respectively. 
  • The data were submitted as a preprint to bioRxiv.
  • The analysis showed minimal impact on neutralizing titers against the Alpha and A.23.1 variants relative to those against the ancestral strain (D614G). 
  • It also showed a modest reduction in neutralizing titers against the Delta (2.1-fold), Gamma (P.1, 3.2-fold), Kappa (3.3-3.4-fold), and Eta (4.2-fold) variants. 
  • A 7.3 or 8.4-fold reduction in neutralizing titers was observed with the additional versions of the Beta variant. 
  • Additionally, an 8.0-fold reduction in neutralizing titers relative to the ancestral strain was observed with A.VOI.V2.
  • Tuesday, Moderna's COVID-19 shot received emergency use approval In India.
  • Price Action: MRNA shares are up 6.08% at $236.30 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!